Market Overview

Patience May Be Needed In Aratana Therapeutics

Patience May Be Needed In Aratana Therapeutics

  • The share price of Aratana Therapeutics Inc (NASDAQ: PETX) has declined 65.6 percent year-to-date, almost touching its 52-week low on November 19.
  • Barclays’ Douglas D. Tsao has maintained an Overweight rating on the company, while lowering the price target from $30 to $15.
  • Although the stock has continued to underperform, Tsao believes that it could be worthwhile to stay with the story due to the potential of the company’s key assets.
  • Analyst Douglas Tsao elaborated that Aratana Therapeutics has provided details about commercial initiatives associated with its lead products, which have enhanced his confidence in the portfolio.

    However, Tsao also mentioned that despite “the maturation of PETX's towards commercialization, PETX shares have continued to underperform,” while also stating that “clinical catalysts for the lead three assets have provided only ephemeral relief for shares, triggering investor frustration and obviously many to give up.”

    Related Link: Hasbro Launches "Companion Pets" For Seniors

    Potential Ahead

    Tsao believes that it is worthwhile staying with the stock, given that there is potential for lead assets to generate sales of more than $200 million. “We feel particularly bullish for Galliprant which launches in a large, established market with a differentiated profile,” Tsao stated.

    On the other hand, when launched, Entyce would be the only FDA-approved drug for inappetence, catering to a population for about 4.1 million dogs. Nocita is also poised to capitalize on the post-surgery pain market.

    According to the Barclays report, about 6 million dogs undergo painful surgery each year in the United States. “Alternative NSAIDs and opioids pose tolerability and scheduling concerns, unlike the non-opioid formulation of Nocita,” the report mentioned.

    Aratana Therapeutics is expected to look at promoting its products overseas going forward, through partnership. “Mgmt seems patient, waiting for signoff from FDA on three major clinical sections of marketing applications, before signing a deal,” Tsao added.

    Image Credit: Public Domain

    Latest Ratings for PETX

    Apr 2019Credit SuisseDowngradesOutperformNeutral
    Jan 2019William BlairDowngradesOutperformMarket Perform
    Jan 2019Stifel NicolausDowngradesBuyHold

    View More Analyst Ratings for PETX
    View the Latest Analyst Ratings


    Related Articles (PETX)

    View Comments and Join the Discussion!

    Posted-In: Barclays Douglas D. Tsao EntyceAnalyst Color Long Ideas Price Target Analyst Ratings Trading Ideas Best of Benzinga

    Latest Ratings

    CHDRBC CapitalMaintains90.0
    WEXWells FargoDowngrades155.0
    CHTRRBC CapitalMaintains570.0
    BLDRRBC CapitalMaintains31.0
    View the Latest Analytics Ratings
    Don't Miss Any Updates!
    News Directly in Your Inbox
    Subscribe to:
    Benzinga Premarket Activity
    Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
    Market in 5 Minutes
    Everything you need to know about the market - quick & easy.
    Fintech Focus
    A daily collection of all things fintech, interesting developments and market updates.
    Thank You

    Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at